Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

Philip J. Mease,¹ Denis Poddubnyy,^2,3,4 Rajan Bajracharya,⁵ Barbara Ink,⁵ Myriam Manente,⁶ Luke Peterson,⁷ Katy White,⁵ Peter Nash,⁸ Lianne S. Gensler⁹

¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, USA; ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada; ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ⁴Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany; ⁵UCB, Slough, UK; ⁶UCB, Braine-l’Alleud, Belgium; ⁷UCB, Morrisville, NC, USA; ⁸School of Medicine, Griffith University, Brisbane, Australia; ⁹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, USA.